Kiniksa Pharmaceuticals International (KNSA) Retained Earnings (2021 - 2025)
Kiniksa Pharmaceuticals International (KNSA) has disclosed Retained Earnings for 5 consecutive years, with -$462.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 11.32% year-over-year to -$462.1 million, compared with a TTM value of -$462.1 million through Dec 2025, up 11.32%, and an annual FY2025 reading of -$462.1 million, up 11.32% over the prior year.
- Retained Earnings was -$462.1 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from -$155000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $6000.0 in Q4 2023 and bottomed at -$720.6 million in Q2 2022.
- Average Retained Earnings over 5 years is -$332.5 million, with a median of -$490.7 million recorded in 2022.
- The sharpest move saw Retained Earnings soared 100.0% in 2023, then plummeted 8685816.67% in 2024.
- Year by year, Retained Earnings stood at -$66000.0 in 2021, then plummeted by 745406.06% to -$492.0 million in 2022, then skyrocketed by 100.0% to $6000.0 in 2023, then tumbled by 8685816.67% to -$521.1 million in 2024, then increased by 11.32% to -$462.1 million in 2025.
- Business Quant data shows Retained Earnings for KNSA at -$462.1 million in Q4 2025, -$155000.0 in Q3 2025, and -$53000.0 in Q2 2025.